摘要
目的探讨艾迪注射液联合化疗治疗老年晚期非小细胞肺癌的临床有效性及安全性。方法将本院2008年1月～2011年11月收治的老年晚期非小细胞肺癌患者180例,随机分为观察组和对照组,每组90例。观察组采用艾迪注射液50mL/d静滴联合化疗,化疗方案分别为多西紫杉醇加顺铂、长春瑞滨加顺铂或吉西他滨加顺铂,对照组单用上述化疗方案治疗,所有患者均接受3～4个周期化疗后评价疗效、毒副作用及生活质量。结果观察组和对照组有效率分别为35.6%和33.3%,比较差异无统计学意义(P>0.05);临床受益率分别为81.1%和67.8%,比较差异有统计学意义(P<0.05),KPS评分改善率分别为54.4%和31.1%,两组差异有统计学意义(P<0.05)。两组均出现胃肠道反应及骨髓抑制,观察组的发生率及严重程度均低于对照组,差异有统计学意义(P<0.05)。结论艾迪注射液联合化疗治疗老年晚期非小细胞肺癌能提高临床受益率及生活质量,减轻化疗毒副作用,易被患者接受。
Objective To investigate the clinical efficacy and safety of Aidi injection combined with chemotherathy in old patients with advanced Non-small eel1 lung cancer. Methods One hundred and eighty cases of old patients with advanced non small cell lung cancer from January 2008 to November 2011 in our hospital were randomized into two groups, the observation group were treated by 50 mE Aidi in 250 mL 5% glucose for intravenous dripping every day combined with one of chemotherapy regimens included TP, GP or NP, the control group were given one of the ehemotherathy regimens, after three or four courses of treatment, efficacy, quality of life and side effects were evaluated for all patients. Results The total effective rate of the observation group was 35.6%, compared with 33.3% of the con- trol group, the difference between two groups was not statistically significant （P 〉 0.05）; the clinical benefit response of the observation was 81.1%, significantly higher than 67.8% of the control group, the difference between two groups was statistically significant than that of control group （P 〈 0.05）; after treatment, the quality of life scores of patients in observation groups were significantly higher than that of control group （P 〈 0.05）, the quality of life scores of the observation group was 54.4%, the control group was 31.3%; Gastrointestinal reaction and bone marrow suppression observed in the observation group was lower than that of the control group （P 〈 0.05）. Conclusion Aidi injection combined with chemotherapy is associated with reduced toxicity of chemotherapy, enhanced clinical benefit response and improved quality of life of patients with advanced Non-small cell lung cancer, is easily accepted by patients.
出处
《中国当代医药》
2013年第7期68-69,71,共3页
China Modern Medicine
基金
江苏省应用基础研究计划(课题编号:SYS201220)
关键词
艾迪注射液
化疗
晚期非小细胞肺癌
临床研究
Aidi injection
Chemotherapy
Advanced Non-small cell lung cancer
Clinical study
